| Website | patrys.com |
| Category | BioTech |
| Phone | 61 3 9670 3273 |
| Employees | |
| Founded | 2006 |
| Description | Cancer Treatment Research |
| Acceptys, 10/08 | $2.82M |
Patrys Limited develops natural human antibody-based therapeutic products for the treatment of lung, pancreatic, gastric, and colon cancers. The company’s lead products include PAT-SM6 and PAT-LM1, which are anti-cancer natural human antibodies for the treatment of multiple cancers; and PAT-SC1 that completed Phase I/IIa trial for the treatment of gastric cancer. It also develops various human antibody discovery programs in infectious diseases for which treatments are needed, including programs in Hepatitis C, malaria, and Staphylococcus A. In addition, the company is exploring opportunities to use its technologies in other disease areas, such as cardiovascular, autoimmune, and central nervous system disorders. Patrys Limited has collaborations with AstraZeneca/Cambridge Antibody Technology and Debiopharm S.A. It operates in Australia, Germany, and the United States. The company was founded in 2006 and is headquartered in Melbourne, Australia.
